IL290260A - Combinations in the oral administration of beta-lactam antibiotics and avivictam derivatives for the treatment of bacterial infections - Google Patents
Combinations in the oral administration of beta-lactam antibiotics and avivictam derivatives for the treatment of bacterial infectionsInfo
- Publication number
- IL290260A IL290260A IL290260A IL29026022A IL290260A IL 290260 A IL290260 A IL 290260A IL 290260 A IL290260 A IL 290260A IL 29026022 A IL29026022 A IL 29026022A IL 290260 A IL290260 A IL 290260A
- Authority
- IL
- Israel
- Prior art keywords
- beta
- orally administered
- bacterial infections
- lactam antibiotics
- treating bacterial
- Prior art date
Links
- 208000035143 Bacterial infection Diseases 0.000 title 1
- NDCUAPJVLWFHHB-UHNVWZDZSA-N avibactam Chemical class C1N2[C@H](C(N)=O)CC[C@@]1([H])N(OS(O)(=O)=O)C2=O NDCUAPJVLWFHHB-UHNVWZDZSA-N 0.000 title 1
- 208000022362 bacterial infectious disease Diseases 0.000 title 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 title 1
- 239000002132 β-lactam antibiotic Substances 0.000 title 1
- 229940124586 β-lactam antibiotics Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962893612P | 2019-08-29 | 2019-08-29 | |
| US201962953852P | 2019-12-26 | 2019-12-26 | |
| PCT/US2020/048119 WO2021041616A1 (en) | 2019-08-29 | 2020-08-27 | Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL290260A true IL290260A (en) | 2022-04-01 |
Family
ID=72433031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL290260A IL290260A (en) | 2019-08-29 | 2022-01-31 | Combinations in the oral administration of beta-lactam antibiotics and avivictam derivatives for the treatment of bacterial infections |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20210060033A1 (enExample) |
| EP (1) | EP4021443A1 (enExample) |
| JP (1) | JP7673052B2 (enExample) |
| KR (1) | KR20220054364A (enExample) |
| CN (1) | CN114302725A (enExample) |
| AU (2) | AU2020337449A1 (enExample) |
| BR (1) | BR112022001344A2 (enExample) |
| CA (1) | CA3152300C (enExample) |
| IL (1) | IL290260A (enExample) |
| MX (1) | MX2022002537A (enExample) |
| WO (1) | WO2021041616A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017290060B2 (en) | 2016-06-30 | 2021-07-22 | Qpex Biopharma, Inc | Boronic acid derivatives and therapeutic uses thereof |
| CN112424209A (zh) | 2018-04-20 | 2021-02-26 | Qpex生物制药有限公司 | 硼酸衍生物及其治疗用途 |
| US12636297B2 (en) | 2019-06-19 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US12637481B2 (en) | 2020-03-18 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| IL297458A (en) | 2020-05-05 | 2022-12-01 | Qpex Biopharma Inc | Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses |
| EP4319760A4 (en) * | 2021-04-05 | 2025-01-08 | Qpex Biopharma, Inc. | CEFTIBUTENE DOSAGE REGIMEN |
| JP2024524372A (ja) * | 2021-07-01 | 2024-07-05 | キューペックス バイオファーマ， インコーポレイテッド | セフチブテンの結晶形態 |
| US20240390335A1 (en) * | 2021-11-09 | 2024-11-28 | Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences | Pharmaceutical composition containing beta-lactam compound and use thereof |
| CN115448920B (zh) * | 2022-10-14 | 2025-01-03 | 广州楷石医药有限公司 | 一种β-内酰胺酶抑制剂及其应用 |
| CN116327764B (zh) * | 2023-04-06 | 2024-04-12 | 浙江医药股份有限公司新昌制药厂 | 一种高效广谱抗耐药菌的药物组合物及其制备方法和其应用 |
| CN119431373B (zh) * | 2024-07-24 | 2025-08-08 | 科睿迪(南京)医药科技有限公司 | 一种β-内酰胺酶抑制剂及其用途 |
| CN122079989A (zh) * | 2024-09-30 | 2026-05-26 | 科睿迪(南京)医药科技有限公司 | 二氮杂二环类β-内酰胺酶抑制剂及其应用 |
| WO2026104587A1 (en) | 2024-11-13 | 2026-05-21 | Adjutec Pharma As | Cyclic boronic acid esters useful as adjuvants in the treatment of bacterial infections |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016046845A1 (en) * | 2014-09-25 | 2016-03-31 | Manu Chaudhary | Stealth, targeted nanoparticles (stn) for oral drug delivery |
| US10085999B1 (en) | 2017-05-10 | 2018-10-02 | Arixa Pharmaceuticals, Inc. | Beta-lactamase inhibitors and uses thereof |
| MX2020004071A (es) | 2017-10-02 | 2020-07-28 | Arixa Pharmaceuticals Inc | Derivados de aztreonam y usos de los mismos. |
-
2020
- 2020-08-27 EP EP20768776.5A patent/EP4021443A1/en active Pending
- 2020-08-27 JP JP2022512720A patent/JP7673052B2/ja active Active
- 2020-08-27 KR KR1020227010180A patent/KR20220054364A/ko not_active Ceased
- 2020-08-27 MX MX2022002537A patent/MX2022002537A/es unknown
- 2020-08-27 WO PCT/US2020/048119 patent/WO2021041616A1/en not_active Ceased
- 2020-08-27 US US17/004,409 patent/US20210060033A1/en not_active Abandoned
- 2020-08-27 BR BR112022001344A patent/BR112022001344A2/pt unknown
- 2020-08-27 CN CN202080060861.2A patent/CN114302725A/zh active Pending
- 2020-08-27 AU AU2020337449A patent/AU2020337449A1/en not_active Abandoned
- 2020-08-27 CA CA3152300A patent/CA3152300C/en active Active
-
2022
- 2022-01-31 IL IL290260A patent/IL290260A/en unknown
-
2023
- 2023-03-13 US US18/182,675 patent/US20230210863A1/en not_active Abandoned
-
2024
- 2024-03-22 AU AU2024201877A patent/AU2024201877B2/en active Active
-
2025
- 2025-04-17 US US19/182,251 patent/US20260158040A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220054364A (ko) | 2022-05-02 |
| EP4021443A1 (en) | 2022-07-06 |
| WO2021041616A1 (en) | 2021-03-04 |
| US20230210863A1 (en) | 2023-07-06 |
| US20210060033A1 (en) | 2021-03-04 |
| US20260158040A1 (en) | 2026-06-11 |
| CA3152300C (en) | 2024-04-30 |
| BR112022001344A2 (pt) | 2022-06-07 |
| MX2022002537A (es) | 2022-03-22 |
| AU2024201877A1 (en) | 2024-04-11 |
| AU2024201877B2 (en) | 2025-05-08 |
| CA3152300A1 (en) | 2021-03-04 |
| JP7673052B2 (ja) | 2025-05-08 |
| CN114302725A (zh) | 2022-04-08 |
| AU2020337449A1 (en) | 2022-03-03 |
| JP2022545291A (ja) | 2022-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3980400A4 (en) | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | |
| NZ617104A (en) | Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor | |
| MX2022002537A (es) | Combinaciones administradas via oral de antibioticos beta-lactama y derivados de avibactam para tratar infecciones bacterianas. | |
| IL267525A (en) | Medicinal combination with amidine-converted beta-lactam compounds and beta-lactamase inhibitors for infections with antibiotic-resistant bacterial strains | |
| GEP20207169B (en) | 3-tetrazolyl-benzene-1,2-disulfonamide derivatives as metallo-beta-lactamase inhibitors | |
| GB201906653D0 (en) | Polypeptides for treatment of bacterial infections | |
| AU2022298746A1 (en) | Beta-lactam derivatives for the treatment of diseases | |
| ZA202309204B (en) | Lactivicin compounds, their preparation and use as antibacterial agents | |
| IL288861A (en) | A drug and its use for the treatment of bacterial infections associated with biofilm | |
| EP4135719A4 (en) | TREATMENT OF CORONAVIRUS INFECTIONS | |
| EP4076420A4 (en) | Compounds for the treatment of bacterial infections and potentiation of antibiotics | |
| NZ706734A (en) | Pharmaceutical compositions useful for the treatment or control of bacterial infections | |
| AU2022488299A1 (en) | Bacteriophage compositions and methods for treatment of bacterial infections | |
| HUE073183T2 (hu) | Különbözõ etiológiájú bakteriális fertõzések kezelésére szolgáló vegyület embereknél | |
| EP4132539A4 (en) | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL INFECTIONS | |
| LT3968956T (lt) | Vietinė farmacinė mupirocino kompozicija, skirta bakterinių infekcijų ir žaizdų gydymui | |
| HK40068281A (en) | Penam derivatives for treating bacterial infections | |
| AU2023901728A0 (en) | Treatment of bacterial infections | |
| AU2021901604A0 (en) | Treatment of bacterial infections | |
| AU2022901468A0 (en) | Treatment of bacterial infections | |
| AU2024346059A1 (en) | Compounds and methods for treating bacterial infections | |
| CA3274987A1 (en) | Bacteriophage compositions and methods for treatment of bacterial infections | |
| HK40116104A (en) | Imidazopyridine amides and related compounds for use in the treatment of bacterial infections | |
| CA3305094A1 (en) | Compounds and methods for treating bacterial infections | |
| CA3302974A1 (en) | Compositions and methods of ent-testosterone for treatment of bacterial infections |